Other
Intratumoral Injection
0
Pipeline Programs↗
8
Active Trials↗
6
Companies Involved↗
Intratumoral Injection is an early-stage landscape with 0 programs across 6 companies. The most active players are Moderna, Binhui Biopharmaceutical Co., Ltd., GONGCHU Biotechnology Co., Ltd.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
18
clinical trials
Completed5 · 28%
Recruiting4 · 22%
Unknown status3 · 17%
Not yet recruiting2 · 11%
Active, not recruiting2 · 11%
Suspended1 · 6%
Other1 · 6%
Clinical Trials
Trial Activity
18 trials
A Phase I/II Study of Intratumoral Injection of SD-101
Completed·—·Phase 1/2·NCT02254772·9 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)